Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance setting.

MLA

Rimel, Bobbie J., et al. “Cytochrome P450 Inhibitor/Inducer Treatment Patterns among Patients in the United States with Advanced Ovarian Cancer Who Were Prescribed or Were Eligible for Poly(Adenosine Diphosphate [ADP]-Ribose) Polymerase Inhibitors in the First-Line Maintenance Setting.” Gynecologic Oncology Reports, vol. 51, Feb. 2024, p. 101332. EBSCOhost, https://doi.org/10.1016/j.gore.2024.101332.

APA

Rimel, B. J., Chase, D. M., Perhanidis, J., Ghazarian, A. A., Du, E. X., Wang, T., Song, J., Golembesky, A. K., Hurteau, J. A., Kalilani, L., Salani, R., & Monk, B. J. (2024). Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance setting. Gynecologic Oncology Reports, 51, 101332. https://doi.org/10.1016/j.gore.2024.101332

Chicago

Rimel, Bobbie J, Dana M Chase, Jessica Perhanidis, Armen A Ghazarian, Ella Xiaoyan Du, Travis Wang, Jinlin Song, et al. 2024. “Cytochrome P450 Inhibitor/Inducer Treatment Patterns among Patients in the United States with Advanced Ovarian Cancer Who Were Prescribed or Were Eligible for Poly(Adenosine Diphosphate [ADP]-Ribose) Polymerase Inhibitors in the First-Line Maintenance Setting.” Gynecologic Oncology Reports 51 (February): 101332. doi:10.1016/j.gore.2024.101332.